Last updated on December 2019

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)


Brief description of study

This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in participants with multiple types of advanced cancer (unresectable and/or metastatic) that: 1) have progressed or been intolerant to standard of care therapy; and 2) are positive for homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD).

Clinical Study Identifier: NCT03742895

Find a site near you

Start Over

Clinical Hospital Saint Luka ( Site 1205)

Saint-Petersburg, Russian Federation
  Connect »

UCSF - Mt. Zion Campus ( Site 0007)

San Francisco, CA United States
  Connect »